Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 574

Sort by

Sort Order Select

Journal Articles

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

Blood (2025) 146 (21): 2608–2611.

https://doi.org/10.1182/blood.2025029391

Published: 2025

Includes: Supplemental data

Journal Articles

Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study

Blood (2025) 146 (Supplement 1): 654.

https://doi.org/10.1182/blood-2025-654

Published: 2025

Journal Articles

Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a phase 2 trial

Andrew Lane, Marlise Luskin, Julia Keating, Nicole Leboeuf, Jacqueline Garcia, Shai Shimony, Rebecca Leonard, Adon Goodpaster, Theresa Nguyen, Ilene Galinsky, Ashleigh Eberly-Puleo, Naval Daver, Nitin Jain, Guillermo Garcia-Manero, Hagop Kantarjian, Marina Konopleva, Anthony Selwyn Stein, Naveen Pemmaraju

Blood (2025) 146 (Supplement 1): 653.

https://doi.org/10.1182/blood-2025-653

Published: 2025

Journal Articles

γ9δ2 T-cell (γ9δ2TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): Results from the phase 1/2 study eviction

Sylvain Garciaz, Pierre-Yves Dumas, Pierre Peterlin, Daniel Morillo, Jose Miguel Torregrosa Diaz, Matthew Ulrickson, Agustin Penedo, Aude De Gassart, Emmanuel Valentin, Maelle Mairesse, George Saad, Patrick Brune, Katrien Lemmens, Noemi Angelosanto, Daniel Olive, Stephan Braun, Naval Daver, Abhishek Maiti

Blood (2025) 146 (Supplement 1): 652.

https://doi.org/10.1182/blood-2025-652

Published: 2025

Journal Articles

Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 651.

https://doi.org/10.1182/blood-2025-651

Published: 2025

Journal Articles

Phase l dose escalation and expansion of ziftomenib in combination with quizartinib in AML

Ghayas Issa, Hagop Kantarjian, Musa Yilmaz, Nicholas Short, Tapan Kadia, Georgina El Hajjar, Courtney DiNardo, Yesid Alvarado, Elias Jabbour, Gautam Borthakur, Naveen Pemmaraju, Farhad Ravandi, Michael Andreeff, Guillermo Garcia-Manero, Naval Daver

Blood (2025) 146 (Supplement 1): 3428.

https://doi.org/10.1182/blood-2025-3428

Published: 2025

Journal Articles

Clinicopathological characteristics and survival outcomes in adults with acute megakaryoblastic leukemia

Vanthana Bharathi, Alexandre Bazinet, Alex Bataller, Naval Daver, Courtney DiNardo, Hussein Abbas, Ian Bouligny, Gautam Borthakur, Fadi Haddad, Naveen Pemmaraju, Steven Kornblau, Wei-Ying Jen, Nicholas Short, Andres Quesada, Guillermo Garcia-Manero, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3405.

https://doi.org/10.1182/blood-2025-3405

Published: 2025

Journal Articles

ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with Acute Myeloid Leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT)

Blood (2025) 146 (Supplement 1): 3399.

https://doi.org/10.1182/blood-2025-3399

Published: 2025

Journal Articles

Treatment intensity may alter the prognostic impact of baseline co-mutations in newly diagnosed FLT3-ITD AML treated with FLT3 inhibitor-based therapy

Sankalp Arora, Jayastu Senapati, Nicholas Short, Musa Yilmaz, Sanam Loghavi, Tapan Kadia, Courtney DiNardo, Gautam Borthakur, Joseph Jabbour, Hannah Goulart, Ghayas Issa, Naveen Pemmaraju, Wei-Ying Jen, Hussein Abbas, Michael Andreeff, Hagop Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi, Naval Daver

Blood (2025) 146 (Supplement 1): 3397.

https://doi.org/10.1182/blood-2025-3397

Published: 2025

Journal Articles

Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study

Amer Zeidan, Anthony Selwyn Stein, Johanna Rimpiläinen, Marja Pyörälä, Timo Siitonen, Brian Ball, Mikko Myllymäki, Joshua Zeidner, Dr. Emma Searle, Ruth Witherall, Petri Bono, Aneel Nimba, Joab Williamson, Sofia Aakko, Maija Hollmén, Mika Kontro, Naval Daver

Blood (2025) 146 (Supplement 1): 236.

https://doi.org/10.1182/blood-2025-236

Published: 2025

Journal Articles

Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 222.

https://doi.org/10.1182/blood-2025-222

Published: 2025

Journal Articles

Identifying novel 'druggable’ targets via Npm1A-turboid fusion and mass spectrometry to overcome genetic or adaptive resistance to menin inhibitors in mtNPM1 AML

Christopher Mill, Warren Fiskus, John Davis, Christine Birdwell, Hanxi Hou, Claes Wahlestedt, Jayastu Senapati, Koji Sasaki, Sanam Loghavi, Branko Cuglievan, Tapan Kadia, Naval Daver, Courtney DiNardo, Kapil Bhalla

Blood (2025) 146 (Supplement 1): 1500.

https://doi.org/10.1182/blood-2025-1500

Published: 2025

Journal Articles

Preclinical activity of investigational menin inhibitor DSP-5336 (Enzomenib)-based combinations against MLL1-rearranged (MLL-r) or mutant-NPM1 AML models

Warren Fiskus, Christopher Mill, Christine Birdwell, John Davis, Kaberi Das, Hanxi Hou, Surbhi Sharma, Steven Warner, Zhizhou Ye, Alicia Matthews, Kevin Philip, Tapan Kadia, Courtney DiNardo, Naval Daver, Kapil Bhalla

Blood (2025) 146 (Supplement 1): 1497.

https://doi.org/10.1182/blood-2025-1497

Published: 2025

Journal Articles

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 680.

https://doi.org/10.1182/blood-2025-680

Published: 2025

Journal Articles

Efficacy and safety of pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm in patients with prior or concomitant hematologic malignancy: Results from the cadenza study

Naveen Pemmaraju, Luca Mazzarella, Giovanni Marconi, David Sallman, Matthew Ulrickson, Roland Walter, Valerio Maisano, Breanne Fishman, Yining Du, Jalaja Potluri, Hagop Kantarjian, Naval Daver

Blood (2025) 146 (Supplement 1): 5195.

https://doi.org/10.1182/blood-2025-5195

Published: 2025

Journal Articles

A phase 1/2, first-in-human, multicenter, open-label trial evaluating the safety, tolerability, and antileukemic activity of Debio 1562M in patients with recurrent refractory acute myeloid leukemia (AML)

Naval Daver, Andrew Sochacki, Monzr M. Al Malki, Eunice Wang, Marianna Muller, Anne Bellon, Sandrine Micallef, David Sallman, Karilyn Larkin

Blood (2025) 146 (Supplement 1): 5194.

https://doi.org/10.1182/blood-2025-5194

Published: 2025

Journal Articles

Acute Myeloid Leukemia with deletion 12p: An adverse-risk disease

William D. Marrero, Mina Abdelmalek, Farah Al Haj, Tapan Kadia, Courtney DiNardo, Elias Jabbour, Sanam Loghavi, Gautam Borthakur, Nicholas Short, Ghayas Issa, Jayastu Senapati, Wei-Ying Jen, Naveen Pemmaraju, Fnu Amritpal Singh, Abhishek Maiti, Guillermo Garcia-Manero, Farhad Ravandi, Naval Daver

Blood (2025) 146 (Supplement 1): 5179.

https://doi.org/10.1182/blood-2025-5179

Published: 2025

Journal Articles

A blood-based protein signature adds to genomic prognostication of survival in TP53-mutated Acute Myeloid Leukemia

Sara Nofal, Jennifer Marvin-Peek, Sanam Loghavi, Jayastu Senapati, Bofei Wang, Fadi Haddad, Nicholas Short, Naval Daver, Ghayas Issa, Koji Sasaki, Gautam Borthakur, Tapan Kadia, Courtney DiNardo, Farhad Ravandi, Guillermo Garcia-Manero, Ehsan Irajizad, Hussein Abbas

Blood (2025) 146 (Supplement 1): 3503.

https://doi.org/10.1182/blood-2025-3503

Published: 2025

Journal Articles

Clonal dynamics of FLT3-ITD positive acute myeloid leukemia following relapse after allogeneic stem cell transplantation

Blood (2025) 146 (Supplement 1): 592.

https://doi.org/10.1182/blood-2025-592

Published: 2025

Journal Articles

Luspatercept response predictors in lower-risk myelodysplastic syndrome

Vanthana Bharathi, Ian Bouligny, Emmanuel Almanza, Alex Bataller, Alexandre Bazinet, Wei-Ying Jen, Niranjan Khaire, Koji Sasaki, Danielle Hammond, Courtney DiNardo, Gautam Borthakur, Tapan Kadia, Naval Daver, Ghayas Issa, Musa Yilmaz, Kelly Chien, Guillermo Montalban-Bravo, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 5648.

https://doi.org/10.1182/blood-2025-5648

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study

Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a phase 2 trial

γ9δ2 T-cell (γ9δ2TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): Results from the phase 1/2 study eviction

Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia

Phase l dose escalation and expansion of ziftomenib in combination with quizartinib in AML

Clinicopathological characteristics and survival outcomes in adults with acute megakaryoblastic leukemia

ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with Acute Myeloid Leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT)

Treatment intensity may alter the prognostic impact of baseline co-mutations in newly diagnosed FLT3-ITD AML treated with FLT3 inhibitor-based therapy

Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study

Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia

Identifying novel 'druggable’ targets via Npm1A-turboid fusion and mass spectrometry to overcome genetic or adaptive resistance to menin inhibitors in mtNPM1 AML

Preclinical activity of investigational menin inhibitor DSP-5336 (Enzomenib)-based combinations against MLL1-rearranged (MLL-r) or mutant-NPM1 AML models

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Efficacy and safety of pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm in patients with prior or concomitant hematologic malignancy: Results from the cadenza study

A phase 1/2, first-in-human, multicenter, open-label trial evaluating the safety, tolerability, and antileukemic activity of Debio 1562M in patients with recurrent refractory acute myeloid leukemia (AML)

Acute Myeloid Leukemia with deletion 12p: An adverse-risk disease

A blood-based protein signature adds to genomic prognostication of survival in TP53-mutated Acute Myeloid Leukemia

Clonal dynamics of FLT3-ITD positive acute myeloid leukemia following relapse after allogeneic stem cell transplantation

Luspatercept response predictors in lower-risk myelodysplastic syndrome

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only